CMS proposes same-day Medicare coverage for some breakthrough devices

CMS has proposed a pathway, called RAPID, that would give some FDA Breakthrough-designated devices national Medicare coverage almost as soon as they clear the agency: a proposed National Coverage Determination issued the same day as FDA market authorization, with a final decision roughly 60 days later for lower-risk devices and 90 days for higher-risk ones [s1]. That is a large compression of a coverage process that normally takes 9 to 12 months, and it is out for public comment through 13 October 2026 [s1].

What RAPID would do

The Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, published as a notice with comment period (CMS-3487-NC) on 11 August 2026, would apply to certain Class II and Class III devices carrying FDA's Breakthrough Device designation [s1]. For an eligible device, CMS would release a proposed NCD on the day FDA grants market authorization, timed to coincide with the public release of FDA's Decision Summary or Summary of Safety and Effectiveness Data [s1]. A final NCD would follow approximately 60 days later for Class II devices and approximately 90 days later for Class III devices [s1]. National coverage would be limited to the FDA-authorized indication [s1].

The scope is deliberately bounded. Eligibility is restricted to devices that, in CMS's words, "demonstrate positive clinical health outcomes for the Medicare population in the premarket phase," and a device generally must have been authorised not more than 18 months before entering the pathway [s1]. In vitro diagnostic products, including diagnostic laboratory tests, are excluded [s1].

Why coverage lags authorisation in the first place

The gap RAPID targets is structural. FDA decides whether a device is safe and effective enough to be sold; Medicare separately decides, through a National Coverage Determination, whether it is "reasonable and necessary" to pay for — and the NCD process has statutorily prescribed timeframes that generally run 9 to 12 months [s1]. During that lag, a device can be on the market but not covered for the roughly 70 million people Medicare serves, of whom about 34 million — some 51 percent as of 2025 — are in Original Medicare, which processed more than 1.1 billion claims [s1].

CMS has tried to close this gap before, and the record is why RAPID is cautious. A January 2021 Medicare Coverage of Innovative Technology (MCIT) rule that would have granted near-automatic coverage to Breakthrough devices was repealed on 15 November 2021 [s1]. Its replacement, the Transitional Coverage for Emerging Technologies (TCET) pathway, was finalised on 12 August 2024 and built around an extensive evidence-development framework rather than automatic payment [s1][s2]. RAPID leans on that same machinery — including the long-standing Coverage with Evidence Development authority CMS has used since 12 July 2006 to pay for promising technologies while studies continue [s1].

It also builds on Parallel Review, a program under which FDA and CMS review a device manufacturer's clinical data at the same time rather than in sequence. Announced as a pilot in 2010 and fully implemented in an October 2016 joint notice, Parallel Review lets the two agencies meet a manufacturer while a pivotal trial is still being designed and then assess the results concurrently — but it "relies upon the technology under review having a quality evidence base to support the clinical analysis for the NCD" [s1]. That caveat is the whole difficulty in one sentence: overlapping the reviews saves time only when the underlying evidence is already strong enough for Medicare's separate question.

The evidence problem, stated plainly

The core tension is that FDA's premarket evidence and Medicare's coverage question are not the same question. CMS's own notice makes the point: FDA may authorise a device on a body of evidence in which "the Medicare population may not be sufficiently represented," so that even after authorisation "there may be insufficient evidence to support" a determination about health outcomes specifically for beneficiaries, who are typically older and sicker than trial participants [s1]. Traditionally CMS relies heavily on health-outcomes data to write an NCD [s1]. Compressing that timeline to zero at the proposed-decision stage means coverage can begin before beneficiary-specific outcomes are known.

RAPID's answer is to condition eligibility on premarket evidence of positive outcomes in the Medicare population and to keep the Coverage with Evidence Development route available, so that coverage can be paired with a requirement to keep generating data [s1]. Whether that is a genuine safeguard or a formality depends on how strictly CMS reads "positive clinical health outcomes for the Medicare population in the premarket phase" when it applies the standard to real devices — a judgement the notice describes but does not resolve. The same underlying question — how much evidence should precede coverage of a new technology — runs through CMS's parallel handling of AI-based cardiovascular software and its rules on prior authorisation.

What to watch

Whether CMS finalises the same-day proposed-NCD timing and the 60- and 90-day windows after comment; how narrowly it defines the premarket evidence bar that gates eligibility; whether manufacturers take up a voluntary pathway that still carries evidence-development obligations; and whether devices covered quickly under RAPID go on to accumulate the beneficiary-specific outcome data that a full national coverage decision would normally demand.